The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Individualized targeted therapy for advanced renal cell carcinoma
Author(s): 
Pages: 129-133
Year: Issue:  3
Journal: World Clinical Drugs

Keyword:  advanced renal cell carcinomatargeted therapyindividualized therapy;
Abstract: Along with the extensive researches about the molecular biology of renal cell carcinoma(RCC) in recent years,targeted therapy has obvious advantages for advanced RCC patients who has lost the chance of operation. Targeted therapy has been used widely in fi rst and second-line treatments of RCC. This review aims to defi ne the clinical application of seven targeted medicines approved by the FDA for the treatment of advanced RCC, such as sunitinib, sorafenib, pazopanib, axitinib, temsirolimus, everolimus and bevacizumab.
Related Articles
No related articles found